Literature DB >> 14627648

Decreased cyclin-dependent kinase 5 (cdk5) activity is accompanied by redistribution of cdk5 and cytoskeletal proteins and increased cytoskeletal protein phosphorylation in p35 null mice.

Janice L Hallows1, Ken Chen, Ronald A DePinho, Inez Vincent.   

Abstract

Cdk5/p35 has been implicated in cytoskeletal protein phosphorylation in normal brain and in many human neurodegenerative disorders. Yet, mouse models of cdk5/p35 hyperactivity have not yielded corresponding changes in cytoskeletal protein phosphorylation. To elucidate the relationship between p35, cdk5, and the neuronal cytoskeleton, we deleted the p35 gene in mice having a pure C57BL/6 background. We found that p35 deficiency leads to a 38% reduction of cdk5 activity in adult brain. In addition, loss of p35 causes an anterograde redistribution of cdk5 toward peripheral neuronal processes. The unusual presence of nonphosphorylated neurofilament (NF) in aberrant axon fascicles and the relocation of tau and MAP2B from cell bodies and proximal neuronal processes to more distal sites of the neuropil in p35-/- mouse brain implicate p35 in neuronal trafficking, particularly in dynein-driven retrograde transport. In many axons of normal brain, cdk5 fails to colocalize with phosphorylated cytoskeletal protein epitopes. This observation, together with an unexpected increase of NF, tau, and MAP2B phosphoepitopes accompanying the decreased cdk5 activity in p35-/- mice, supports the idea that cdk5 does not phosphorylate cytoskeletal proteins directly. Rather, in structures where cdk5 does colocalize with phosphorylated cytoskeletal protein epitopes, it may function as a negative regulator of other proline-directed kinases that directly phosphorylate the proteins. Evidence for increased glycogen synthase kinase 3beta (GSK3beta) activity in p35-/- mice suggests that GSK3beta may be one such kinase regulated by cdk5. Our studies illustrate that p35 regulates the subcellular distribution of cdk5 and cytoskeletal proteins in neurons and that cdk5 has a hierarchical role in regulating the phosphorylation and function of cytoskeletal proteins.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14627648      PMCID: PMC6740918     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  37 in total

1.  Impairments in fast axonal transport and motor neuron deficits in transgenic mice expressing familial Alzheimer's disease-linked mutant presenilin 1.

Authors:  Orly Lazarov; Gerardo A Morfini; Gustavo Pigino; Archana Gadadhar; Xiangjun Chen; John Robinson; Hanson Ho; Scott T Brady; Sangram S Sisodia
Journal:  J Neurosci       Date:  2007-06-27       Impact factor: 6.167

2.  The role of Cdk5-mediated apurinic/apyrimidinic endonuclease 1 phosphorylation in neuronal death.

Authors:  En Huang; Dianbo Qu; Yi Zhang; Katerina Venderova; M Emdadul Haque; Maxime W C Rousseaux; Ruth S Slack; John M Woulfe; David S Park
Journal:  Nat Cell Biol       Date:  2010-05-16       Impact factor: 28.824

Review 3.  Therapeutic strategies for Alzheimer's disease.

Authors:  Donna M Barten; Charles F Albright
Journal:  Mol Neurobiol       Date:  2008-06-26       Impact factor: 5.590

4.  FKBP51 inhibits GSK3β and augments the effects of distinct psychotropic medications.

Authors:  N C Gassen; J Hartmann; A S Zannas; A Kretzschmar; J Zschocke; G Maccarrone; K Hafner; A Zellner; L K Kollmannsberger; K V Wagner; D Mehta; S Kloiber; C W Turck; S Lucae; G P Chrousos; F Holsboer; E B Binder; M Ising; M V Schmidt; T Rein
Journal:  Mol Psychiatry       Date:  2015-04-07       Impact factor: 15.992

5.  Hippocampal glycogen synthase kinase 3β is critical for the antidepressant effect of cyclin-dependent kinase 5 inhibitor in rats.

Authors:  Gang Li; Ting Liu; Xiangqian Kong; Lei Wang; Xing Jin
Journal:  J Mol Neurosci       Date:  2014-02-22       Impact factor: 3.444

6.  Both cyclin I and p35 are required for maximal survival benefit of cyclin-dependent kinase 5 in kidney podocytes.

Authors:  Yoshinori Taniguchi; Jeffrey W Pippin; Henning Hagmann; Ronald D Krofft; Alice M Chang; Jiong Zhang; Yoshio Terada; Paul Brinkkoetter; Stuart J Shankland
Journal:  Am J Physiol Renal Physiol       Date:  2012-01-18

7.  Special Issue on "Cdk5 and Brain Disorders": Prologue.

Authors:  Jyotshnabala Kanungo
Journal:  Brain Disord Ther       Date:  2012-05-31

8.  The Notch signaling inhibitor DAPT down-regulates cdk5 activity and modulates the distribution of neuronal cytoskeletal proteins.

Authors:  Jyotshnabala Kanungo; Ya-Li Zheng; Niranjana D Amin; Harish C Pant
Journal:  J Neurochem       Date:  2008-07-04       Impact factor: 5.372

9.  Neurodegeneration and neuroinflammation in cdk5/p25-inducible mice: a model for hippocampal sclerosis and neocortical degeneration.

Authors:  David Muyllaert; Dick Terwel; Anna Kremer; Kristina Sennvik; Peter Borghgraef; Herman Devijver; Ilse Dewachter; Fred Van Leuven
Journal:  Am J Pathol       Date:  2008-01-17       Impact factor: 4.307

10.  The neuroprotective effects of cyclin-dependent kinase-5 inhibition in mice with Niemann-Pick disease type C.

Authors:  Youguo Hao; Dengji Pan; Min Zhang; Jinzhi Xu; Linjuan Li; Jiajun Wei; Xuezhen Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.